Achieve Life Sciences Inc
NASDAQ:ACHV

Watchlist Manager
Achieve Life Sciences Inc Logo
Achieve Life Sciences Inc
NASDAQ:ACHV
Watchlist
Price: 4.4 USD 0.46%
Market Cap: 224.8m USD

ACHV's latest stock split occurred on Jul 31, 2020

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, ACHV traded at 0.6 per share. Afterward, the share price was about 13.63.

The adjusted shares began trading on Jul 31, 2020. This was ACHV's 4th stock split, following the previous one in May 24, 2018.

Last Splits:
Jul 31, 2020
1-for-20
May 24, 2018
1-for-10
Aug 3, 2017
1-for-11
Aug 21, 2008
1-for-18
Pre-Split Price
12 0.6
Post-Split Price
13.63
Before
After
Last Splits:
Jul 31, 2020
1-for-20
May 24, 2018
1-for-10
Aug 3, 2017
1-for-11
Aug 21, 2008
1-for-18

Achieve Life Sciences Inc
Stock Splits History

ACHV Stock Splits Timeline
Jul 31, 2020
Jul 31, 2020
Split 1-for-20
/0.05
Pre-Split Price
12 0.6
Post-Split Price
13.63
Before
After
May 24, 2018
May 24, 2018
Split 1-for-10
/0.1
Pre-Split Price
200 1
Post-Split Price
207.8
Before
After
Aug 3, 2017
Aug 3, 2017
Split 1-for-11
/0.090909090909091
Pre-Split Price
880 0.4
Post-Split Price
852
Before
After
Aug 21, 2008
Aug 21, 2008
Split 1-for-18
/0.055555555555556
Pre-Split Price
11 084.04 0.2799
Post-Split Price
10 604
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
85 85 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60 60 USD N/A
Dec 5, 2025
Cirralto Ltd
OTC:CROTF
1-for-10
/10
0.0121 0.0121 USD N/A
Dec 3, 2025
Ionic Rare Earths Ltd
OTC:IXRRF
1-for-30
/30
0.0116 0.0116 USD N/A
Load More

Achieve Life Sciences Inc
Glance View

Market Cap
232.4m USD
Industry
Biotechnology

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).

ACHV Intrinsic Value
2.72 USD
Overvaluation 38%
Intrinsic Value
Price
Back to Top